Current Report Filing (8-k)

  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 11, 2016

ALBANY MOLECULAR RESEARCH, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware	001-35622	14-1742717
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

 

26 Corporate Circle, P.O. Box 15098, Albany, NY	12212
(Address of principal executive offices)	(Zip Code)

 

Registrant’s telephone number, including area code: [phone]

 

 (Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below) :

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

 

  

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.

   

On April 11, 2016, Veronica G.H. Jordan, Ph.D. informed the Board of Directors (the “Board of Directors”) of Albany Molecular Research, Inc. (the “Company”) that she will not stand for re-election when her current term expires at the Company’s 2016 Annual Meeting of Stockholders due to her intention to retire from the Board of Directors, the Compensation Committee of the Board of Directors and the Audit Committee of the Board of Directors, effective June 1, 2016, in order to devote further time and attention to her other business ventures. Dr. Jordan’s decision was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 12, 2016	ALBANY MOLECULAR RESEARCH, INC.
	By:	/s/ Lori M. Henderson
		Name: Lori M. Henderson
		Title: Senior Vice President, General Counsel & Secretary